PT  - JOURNAL ARTICLE
AU  - Argyris Tzouvelekis
AU  - Katerina Antoniou
AU  - Michael Kreuter
AU  - Matthew Evison
AU  - Torsten Blum
AU  - Venerino Poletti
AU  - Paolo Spagnolo
AU  - Francesco Bonella
AU  - Bogdan Girgoriu
AU  - Carlo Vancheri
AU  - Jacques Cadranel
AU  - Demosthenes Bouros
TI  - Late Breaking Abstract - The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey
AID  - 10.1183/13993003.congress-2019.OA249
DP  - 2019 Sep 28
TA  - European Respiratory Journal
PG  - OA249
VI  - 54
IP  - suppl 63
4099  - http://erj.ersjournals.com/content/54/suppl_63/OA249.short
4100  - http://erj.ersjournals.com/content/54/suppl_63/OA249.full
SO  - Eur Respir J2019 Sep 28; 54
AB  - Background: Currently there is major lack of knowledge on the diagnostic and therapeutic management of patients with Idiopathic Pulmonary Fibrosis (IPF) and lung cancer (LC).Objectives: 1) To identify variations in diagnostic and management strategies across different institutions. 2) To provide rationale for a consensus statement on this issue.Results: This was a joint-survey by ERS Assemblies 8, 11 ad 12. The survey consisted of 25 questions. 494 physicians from 68 different countries and 5 continents responded to the survey. 94% of participants were pulmonologists and 1.8% thoracic surgeons and 1.9% oncologists. 67% and 21.6% were from University and non-University hospitals, respectively and 26.3% were treating > 50 patients with IPF per year. 97.7% involved MDT approaches on diagnosis and management. Regular low-dose HRCT scan was used by 49.5% of the respondents to screen for LC in IPF. PET scan and EBUS bronchoscopy was performed by 60% and 88% to diagnose nodular lesions with mediastinal lymphadenopathy in patients with advanced and mild IPF, respectively. 83% of respondents continue anti-fibrotics following LC diagnosis; safety precautions during surgical interventions including low-tidal volume were applied by 67%. Stereotactic radiotherapy was used to treat patients with advanced IPF (DLCO<35%) and otherwise operable NSCLC in 54% of respondents and doublet platinum regimens and immunotherapy for metastatic disease in 25% and 31.9%, respectively. Almost all participants (93%) replied that a consensus statement for the management of these patients is necessary.Conclusions: Considering the heterogeneous practices in LC-IPF became evident, most respondents called for a consensus statement.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, OA249.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).